Jihoon Hwang

President & CEO, Linical Korea

Jihoon Hwang

Message

The global clinical study market has been increasing and Korea’s share has also been increasing continuously. Korea has become a world center of clinical studies. For example, there were only 42 KFDA (Korea Food and Drug Administration) approvals of clinical studies in 1998, but in 2015 there were 675 approvals. Among them, 296 approvals were from global trials. The data from “Korea National Enterprise for Clinical Trials, KoNECT” shows that Seoul was consecutively ranked as the city which has the largest clinical study numbers in the world from 2011 to 2014.
In Korea, there are about 25 CROs and Linical Korea is making its mark as one of the most promising. Linical Korea has conducted many clinical trials for local and global clients, and has demonstrated an excellent reputation as a top provider. Our goal is to become a CRO who clients consider as their preferred business partner for drug development. Pursuing our goal, we will continue supporting our clients with high quality in conducting clinical studies.